Tuberculosis Clinical Trial
Official title:
A Phase III Trial in Subjects Suspected to Have Tuberculosis, Comparing the Diagnostic Performance of C-Tb to QuantiFERON®-TB Gold In-Tube, in Combination With a Double Blind Randomized Split Body Safety Assessment of C-Tb Versus 2 T.U. Tuberculin PPD RT23 SSI (PPD)
Tuberculosis (TB) continues to be one of the most serious bacterial infections worldwide and
therefore new improved diagnostic tests are needed to help doctors in diagnosing TB.
The new skin test is named C-Tb. Like the current tuberculin skin test, PPD, the C-Tb test
is injected just under the skin and will, when positive, show redness and/or swelling at the
injection site while a negative test will leave no reactions. The investigators hope that
this new C-Tb skin test will be more precise (specific) than the PPD test, as the PPD test
e.g. may show a reaction if the person tested is BCG vaccinated.
The aim of this trial is to test the C-Tb skin test in volunteers suspected of having TB
disease.
With focus on age, HIV status and CD4 count the following analyses are done (in an overall
perspective):
- To compare the C-Tb test to a blood test, the QuantiFERON test.
- To compare the C-Tb test to the PPD test that is currently being used.
- To assess the safety of the C-Tb test.
The TESEC-05 trial is an open comparison of the diagnostics performance of C-Tb compared to
the QuantiFERON®-TB Gold In-Tube, in combination with a double-blind randomized split-body
safety assessment of C-Tb versus to 2 T.U. Tuberculin PPD RT23 SSI.
The trial is a multi-centre Phase III clinical trial designed specifically to address C-Tb
in relation to the paediatric population and to HIV infection. The intention is to evaluate
how the C-Tb test performs in the paediatric population with respect to safety, and to
ensure that SSI will be able to extrapolate data obtained in an adult population to the
paediatric population.
Furthermore, the intention is both to evaluate the diagnostic performance and safety of C-Tb
in HIV infected individuals and to evaluate whether SSI will be able to extrapolate data
obtained in a non-HIV population to a HIV population.
The trial population will consist of paediatric participants with suspected TB infection and
adult participants suspected to have TB disease. Furthermore a control group of 100 children
between 5 - 11 years of age with no symptoms or known exposure will be recruited from an
area with a "low" prevalence of TB (an area with an incidence rate < 299/100,000 per year,
the average rate of TB in South Africa in 2005 was 645/100,000 per year.
The trial will be conducted in South Africa where the prevalence of HIV infection is high
and MTb infections are endemic.
BCG vaccination at birth has been common practice since 1961 in South Africa. Thus most of
the participants are presumed BCG vaccinated.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |